Saito Mitsuru, Marumo Keishi
Department of Orthopaedic Surgery, Jikei University School of Medicine, Tokyo, Japan.
Clin Calcium. 2012 Mar;22(3):343-55.
Parathyroid hormone (PTH) acts as an anabolic agent and is used for the treatment for osteoporosis. Daily or once-weekly self-administered subcutaneous injection of human PTH (1-34) (teriparatide) increased bone mineral density (BMD) compared to a placebo in post-menopausal osteoporotic patients. Recently, data have accumulated that collagen cross-link formation in bone affect bone strength. In fact, impaired enzymatic cross-linking and/or an increase in non-enzymatic cross-links, pentosidine, which is a surrogate marker of advanced glycation end products (AGEs) , in bone collagen have been proposed as a major cause of bone fragility in osteoporosis. We reported that teriparatide improves bone collagen cross-link formation, microarchitecture, and bone mass, resulting in the increase of bone strength (Saito M : Osteoporos Int 22 : 2373-83, 2011) . In this review, we described how teriparatide improve bone collagen cross-link formation and mineral qualities.
甲状旁腺激素（PTH）作为一种促合成代谢药物，用于治疗骨质疏松症。与安慰剂相比，绝经后骨质疏松症患者每日或每周一次自行皮下注射人PTH（1-34）（特立帕肽）可增加骨矿物质密度（BMD）。最近，有数据表明骨中胶原交联的形成会影响骨强度。事实上，骨胶原中酶促交联受损和/或非酶促交联（戊糖苷，晚期糖基化终产物（AGEs）的替代标志物）增加被认为是骨质疏松症中骨脆性的主要原因。我们报道特立帕肽可改善骨胶原交联形成、微观结构和骨量，从而提高骨强度（斋藤M：《骨质疏松症国际》22：2373-2383，2011）。在本综述中，我们描述了特立帕肽如何改善骨胶原交联形成和矿物质质量。
